ECCN European Conference on Clinical Neuroimaging - PARIS France 2020

INVITED SPEAKERS IN 2020



JAVIER ARBIZU

March 02, 2.15 - 2.45am - "Procedural guidelines on 18FDopa in parkinsonism."

Dr. Javier Arbizu, MD, PhD, is Professor of Radiology and Nuclear Medicine at the University of Navarra, and Consultant of the Department of Nuclear Medicine at the Clinica Universidad de Navarra, (Pamplona, Spain). During his career he has had the opportunity to work in the Nuclear Cardiology Laboratory at the Mount Sinai Medical Center, (New York, USA), PET Center of the Department of Radiology at the University of Pittsburgh Medical Center (Pittsburgh, USA), and MRC-Hammersmith (London, UK).
As Nuclear Medicine physician, he has dedicated most of his time to work on neuroimaging both in clinical assistance and research, particularly interested in clinical and prodromal neurodegenerative disorders, and neurooncology. He is currently leading the Spanish amyloid PET imaging registry project (PET ADDS) founded by the Government of Spain and Industry.
Dr. Arbizu is currently vicepresident of the Brain Imaging Council of the SNMMI, and was involved in the Neuroimaging Committee of the EANM and the executive board of the Spanish Society of Nuclear Medicine (SEMNIM). He is member of the Editorial Board of the Eur J Nucl Med Mol Imaging, Rev Esp Med Nucl Med Imagen Mol, and Diagnostics.
 

ALESSANDRA DODICH

March 03, 9.15 - 9.45am - "Analyical and clinical validity of tau PET tracers in the perspective of clinical use."

Alessandra Dodich works as a researcher at the Centre for Mind/Brain Sciences, in Trento, Italy. She completed her PhD in Cognitive Neuroscience in 2015 at San Raffaele University (Milan, Italy) and she worked as post-doc fellow in the Laboratory of Neuroimaging and Innovative Molecular Tracers (Geneva, Switzerland) focused on the use of molecular neuroimaging to the clinical and physio-pathological evaluation of neurodegenerative pathologies associated with dementia. Her main research interests include the study in neurodegenerative disease of the relationship between clinical presentation and brain pathological burden evaluated through neuroimaging techniques.
 

NORBERT GALLDIKS

March 02, 10.00 - 10.30am - "PET imaging in brain metastasis."

Norbert Galldiks, MD, is a Professor of Neurology, Senior Neurologist and Senior Neuro-Oncologist at the Dept. of Neurology at the University Hospital Cologne in Germany. He studied medicine at the University of Cologne and Cornell University / Memorial Sloan-Kettering Cancer Center, New York. In 2002, he qualified in medicine and received his MD from the University of Cologne, Germany. After a postdoctoral fellowship at the Max-Planck-Institute for Neurological Research in Cologne (PET laboratory) he obtained his training in Neurology at the University Hospital Cologne. Furthermore, he is Senior Research Scientist at the Institute of Neuroscience and Medicine (INM-3) at the Research Center in Juelich, Germany.
 
Dr. Galldiks is also Head of the Outpatient Clinic for Neuro-Oncology at the Dept. of Neurology at the University Hospital Cologne, a Board of Directors member of the Brain Tumor Center at the University Hospital Cologne, and leader of the PET Response Assessment in Neuro-Oncology Working Group (PET/RANO). He developed multiple investigator-initiated neuroimaging studies in brain tumor patients and also served in numerous national and international phase II and III clinical trials for brain tumor therapy. Additionally, he co-authored in collaboration with international major societies in the field (RANO / EANO / EANM / SNMMI) practice guidelines for PET imaging in glioma patients. Currently, he is Associate Editor for the journals Neuro-Oncology Advances and Neuro-Oncology Practice.
 
Dr. Galldiks has over 200 publications, predominantly focusing on the evaluation of gliomas and brain metastasis using PET, conventional and advanced MRI, hybrid PET/MRI, and Radiomics techniques.
 

ADRIEN HOLZGREVE

March 02, 10.30 - 11.00am - "Mitochondrial translocator protein (TSPO) imaging in glioma."

Adrien Holzgreve attended Medical School at the University of Munich (LMU), the University of Heidelberg and Charité University Berlin with stays abroad at Fann University in Dakar, Senegal, and at Harvard Medical School in Boston, USA.
Dr. Holzgreve currently is a resident in the Department of Nuclear Medicine at LMU Munich University Hospital. His research interests center around clinical and experimental neurooncology with a special focus on the molecular imaging of brain tumors. Dr. Holzgreve is a member of EANM and EANO.
 

IAN LAW

March 02, 9.30 - 10.00am - "Neurooncological applications of PET/MRI in clinical and research use."

Ian Law is Professor at the University of Copenhagen, Denmark, and Chief Physician at the Dept of clinical physiology, nuclear medicine and PET, Rigshospitalet. He has written his Ph.D and habilitation thesis (DMSc) in PET perfusion imaging. Presently his primary research interests are clinical implementation and research use of PET/CT and PET/MRI with focus on neurooncology, and neurodegeneration.
 

ISADORA LOPES ALVES

March 03, 9.45 - 10.15am - "Amyloid PET for earlier etiological diagnosis and individual risk profiling."

Isadora Lopes Alves is a postdoctoral researcher at the Radiology and Nuclear Medicine Department at VUmc, in Amsterdam. After obtaining her BSc in Medical Physics at PUCRS (Pontifícia Universidade Católica do Rio Grande do Sul) in Brazil, she moved to the Netherlands and obtained her PhD in the topic of PET quantification from the University of Groningen in 2017. Currently, Isadora is one of the lead scientists and project manager for the AMYPAD Consortium (Amyloid Imaging to Prevent Alzheimer’s Disease), and jointly leads the project's Disease Modeling team. Her current research focuses on the longitudinal modeling of PET-based amyloid deposition across the Alzheimer’s disease (AD) spectrum, the application of multimodal advanced statistical modeling approaches for determining the natural history of AD, as well as the development of methodological approaches for cross-radiotracer analyses of amyloid burden using PET.

 

SILVIA MORBELLI

March 02, 1.45 - 2.15pm - "Why new procedural guidelines and what's new on DaT SPECT."

Silvia Morbelli (MD, PhD) is Associate Professor of Nuclear Medicine at the University of Genoa. She works as Nuclear Medicine physician at San Martino University Hospital since 2007. She obtained a PhD in Applied Neurosciences in 2010.  She has made contributions related to the use of neuroimaging tools as diagnostic and prognostic biomarkers in the earliest and preclinical stages of Neurodegenerative Dementia and Parkinsonian Syndromes. She is especially interested in the use of Molecular Imaging to disclose networks underlying different clinical phenotypes as well as brain reserve in Alzheimer’s and Lewy Body Diseases. She is a member of the Neuroimaging Committee of the European Association of Nuclear Medicine since 2015 and she will serve as Chair of the Committee from January 2020.
 

MICHAEL RULLMANN

March 03, 10.45 - 11.15am - "Hybrid PET/MRI in neurodegenerative disorders."

Dr. Michael Rullmann holds a diploma in medical computer science awarded by Leipzig University, where he also completed his PhD in theoretical medicine. He works as a post-doctoral researcher at the Department of Nuclear Medicine and as guest researcher at the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig, Germany. His area of expertise includes processing, analysing and modeling of different neuroimage modalities (PET, MRI).
 

ANDREA VARRONE

March 02, 2.45 - 3.15pm - "New PET tracers for presynaptic dopaminergic imaging."

Andrea Varrone, MD, PhD, Associate Professor of Nuclear Medicine at the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. He is Director of the Brain Molecular Imaging Centre (BMIC), a core facility for molecular imaging studies of the brain using PET. He is research group leader of molecular imaging in neurodegenerative disorders. The focus of his research is the development of PET imaging markers for the study of neurodegenerative disorders, in particular Parkinson´s and Alzheimer´s disease. He is author of more than 120 papers, including reviews and procedural guidelines; HI 33 (Google Scholar), 5459 citations. 


               Share Share

New comment:

News | general information | Archives | Press Presse | Newsletters | DOCUMENTS